Looks like you’re on the UK site. Choose another location to see content specific to your location

MHRA Announces Codeine to be Reclassified as Prescription-Only
The Medicines and Healthcare Products Regulatory Agency has stated that, due to issues surrounding misuse of codeine linctus, the treatment will be, once again, for prescription use only.
This announcement follows the summer 2023 MHRA discussion that investigated reports of codeine linctus misuse and the increasing risks of substance abuse and overdosing.
Safety data suggests that codeine linctus is being abused for its opioid properties for recreational purposes, diverging from its intended use as a cough treatment.
Codeine linctus is most commonly used in the treatment of coughs for those over the age of 18.
Alison Cave, the head safety officer of the MHRA, stated, “Patient safety is our top priority. Codeine linctus is an effective medicine for long-term dry cough, but as it is an opioid, its misuse and abuse can have major health consequences.”
© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard